Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Seneca Completes Stem Cell Manufacturing Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

Seneca Completes Stem Cell Manufacturing Facility

Will be used to manufacture the company's lead stem cell therapy for clinical trials within China

By: Contract Pharma

Contract Pharma Staff

Seneca Biopharma, a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, has completed its new cell manufacturing facility in Suzhou, China. The facility will be used to manufacture NSI-566, the company’s lead stem cell therapy, for clinical trials within China, including a non-GCP compliant Phase II trial currently underway for the treatment of chronic ischemic stroke at the BaYi Brain Hospital in Beijing. Stroke is the leading cause of death and disability in China.
 
“Completion of our new facility in Suzhou is a key milestone in Seneca’s product development strategy,” said Ken Carter, executive chairman, Seneca. “This facility will allow us to manufacture cells to support our current and future clinical trials in China. I’d like to personally thank the staff who have been able to move forward on this plan while maintaining their safety during these uncertain times.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics